Padmanabh P. Bhatt Sells 700 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the transaction, the vice president now directly owns 10,149 shares of the company’s stock, valued at $402,103.38. The trade was a 6.45 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Supernus Pharmaceuticals Stock Down 0.8 %

SUPN opened at $38.69 on Friday. The company has a market cap of $2.14 billion, a PE ratio of 36.16 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $39.88. The company has a 50-day moving average price of $37.10 and a 200 day moving average price of $34.39.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. The business had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business’s revenue was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.29) earnings per share. As a group, sell-side analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on SUPN. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cantor Fitzgerald started coverage on Supernus Pharmaceuticals in a research note on Monday, January 6th. They set an “overweight” rating and a $57.00 target price for the company. Finally, Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can grew its holdings in shares of Supernus Pharmaceuticals by 1,508.0% during the second quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company’s stock worth $3,287,000 after buying an additional 109,088 shares in the last quarter. Marshall Wace LLP purchased a new stake in Supernus Pharmaceuticals during the 2nd quarter valued at about $1,967,000. Cubist Systematic Strategies LLC raised its holdings in Supernus Pharmaceuticals by 98.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 79,632 shares of the specialty pharmaceutical company’s stock valued at $2,130,000 after acquiring an additional 39,479 shares during the last quarter. Millennium Management LLC lifted its stake in Supernus Pharmaceuticals by 395.1% in the 2nd quarter. Millennium Management LLC now owns 161,332 shares of the specialty pharmaceutical company’s stock worth $4,316,000 after purchasing an additional 128,743 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Supernus Pharmaceuticals by 7.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,554 shares of the specialty pharmaceutical company’s stock worth $710,000 after purchasing an additional 1,870 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.